In this webinar, scientists from PACT Pharma Inc. and Thermo Fisher Scientific discuss how scalable, closed instruments can enable automation and standardization of the end-to-end manufacturing workflow—from cell isolation and activation to genetic modification and expansion.
- Scaling and automating the cell therapy manufacturing process
- Safety and regulatory advantages of non-viral transfection for cell therapy
- A highly efficient non-viral precision genome engineering process to manufacture personalized cell therapies for solid tumors
